Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 3,097 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Completed Phase 1Phase 2 Interventional

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

NCT00038168
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Taxol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 30, 2026, 12:16 AM EDT
Active, not recruiting Not applicable Interventional

Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers

NCT02774759
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs
Interventions
Accelerometer, Questionnaires, Fitness Test, Resistance Training, Aerobic Exercise, Telephone Coaching/Phone Calls, Video Chat Sessions
Device · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

NCT00506779
View directory record Official record
Conditions
Uterine Cancer
Interventions
Imatinib Mesylate, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Not applicable Interventional

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

NCT06736600
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
Goal Attainment Scaling (GAS)
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT03041636
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia
Interventions
Ruxolitinib, Ruxolitinib Phosphate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 30, 2026, 12:16 AM EDT
Completed No phase listed Observational

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

NCT02203136
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tissue Biopsy, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 30, 2026, 12:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spirituality/Religiosity in Patients and Caregivers

NCT00634257
View directory record Official record
Conditions
Advanced Cancer, Solid Tumors
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 30, 2026, 12:16 AM EDT
Not yet recruiting Phase 2 Interventional

A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy

NCT07856719
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Colchicine, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT03210662
View directory record Official record
Conditions
Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
External Beam Radiation Therapy, Pembrolizumab
Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Not listed No phase listed Observational

Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients

NCT00354705
View directory record Official record
Conditions
Colon Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 30, 2026, 12:16 AM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)

NCT05361551
View directory record Official record
Conditions
Liver Ablation, Hepatic
Interventions
Liver ablation
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

NCT00080795
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

NCT01775930
View directory record Official record
Conditions
Kidney Cancer
Interventions
Carfilzomib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 30, 2026, 12:16 AM EDT
Active, not recruiting Early Phase 1 Interventional

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

NCT05495464
View directory record Official record
Conditions
Lymphoma, Mantle Cell Lymphoma
Interventions
Acalabrutinib, Rituximab, Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Completed No phase listed Observational

Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing

NCT00909207
View directory record Official record
Conditions
Advanced Cancers, Hematologic Diseases, Solid Tumors
Interventions
Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 30, 2026, 12:16 AM EDT
Suspended No phase listed Observational

The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast Conserving Surgery on Postoperative Treatment

NCT07140965
View directory record Official record
Conditions
Breast Cancer
Interventions
Pegulicianine Fluorescence-Guided Surgery, Digital Breast Tomosynthesis, Breast Conserving Therapy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy

NCT00526331
View directory record Official record
Conditions
Esophageal Diseases, Gastrointestinal Diseases, Disorder of the Genitourinary System, Gynecologic Diseases, Kidney Diseases, Liver Diseases, Pancreatic Diseases, Prostate Cancer, Spinal Disease
Interventions
Vigileo Monitor, FloTrac Sensor
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Oct 30, 2026, 12:16 AM EDT
Not yet recruiting Not applicable Interventional

ACT-GEN (Adherence And Care Tracking In GENetic Cancer Syndromes)

NCT07565467
View directory record Official record
Conditions
ACT-GEN, Genetic Cancer Syndromes
Interventions
Standard of care, Interviews
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 1 Interventional

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

NCT00645541
View directory record Official record
Conditions
Breast Cancer
Interventions
Axillary Reverse Mapping
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 1Phase 2 Interventional

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

NCT00077142
View directory record Official record
Conditions
Liver Cancer
Interventions
TAC-101
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Not applicable Interventional Results available

Fibrin Melanoma Axillary Node Study in Patients With Melanoma

NCT00504582
View directory record Official record
Conditions
Melanoma
Interventions
Fibrin Sealant
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 30, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available

Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis

NCT02784496
View directory record Official record
Conditions
Myelofibrosis
Interventions
Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 30, 2026, 12:16 AM EDT
Suspended Early Phase 1 Interventional

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

NCT05620342
View directory record Official record
Conditions
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
Interventions
iC9.GD2.CAR.IL-15 T Infusion
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 12:16 AM EDT
Terminated Phase 2 Interventional Results available

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

NCT01200342
View directory record Official record
Conditions
Melanoma
Interventions
Genasense, Paclitaxel, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 30, 2026, 12:16 AM EDT